Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:

NCT ID: NCT00567424 Withdrawn - Epilepsy Clinical Trials

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Start date: July 2006
Phase: Phase 2
Study type: Interventional

Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin

NCT ID: NCT00559169 Withdrawn - Catamenial Epilepsy Clinical Trials

Verapamil and Catamenial Epilepsy

Start date: February 2009
Phase: N/A
Study type: Interventional

One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

NCT ID: NCT00532376 Withdrawn - Depression Clinical Trials

fMRI Investigation of Depression in Patients With Epilepsy

Start date: September 2005
Phase: N/A
Study type: Observational

Depression is very common in epilepsy. Depression is the strongest predictor of poor quality of life in patients with epilepsy. The biological basis for depression in epilepsy remains poorly understood. This study uses functional MRI (fMRI) to examine brain response to emotional and non-emotional stimuli in healthy control subjects and in patients with epilepsy who are either depressed or not depressed. Results from this study will contribute to a better understanding of depression in epilepsy, which may eventually inform development of better treatment modalities..

NCT ID: NCT00530413 Withdrawn - Epilepsy Clinical Trials

Study of Phenobarbital Inhibition of Catamenial Epilepsy

Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy. We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.

NCT ID: NCT00175864 Withdrawn - Epilepsy Clinical Trials

Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.

NCT ID: NCT00175851 Withdrawn - Epilepsy Clinical Trials

Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy

Start date: May 2008
Phase: Phase 3
Study type: Interventional

This is a safety and efficacy study of add-on therapy with seletracetam in epilepsy patients who have participated in a previous seletracetam study